Teva Pharmaceuticals has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva's US generic versions of AstraZeneca's Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages. Under the terms of the omeprazole agreement, Teva will obtain a release for all past sales of its generic omeprazole and will continue to market its product in the US and will make a one-time payment to AstraZeneca. As part of the esomeprazole agreement, AstraZeneca has granted Teva a license, subject to regulatory approval, to enter the US market with its generic esomeprazole delayed-release capsules on May 27, 2014, or earlier in certain circumstances. Additional details were not disclosed. Merck Sharp & Dohme Corp, through KBI Inc. and KBI-E, and under the terms of Merck's restructured partnership with AstraZeneca, announced in 1998, also entered into the settlement agreements.
No comments:
Post a Comment